Imugene Limited

Imugene Limited

IUGNF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$10.82M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Imugene LimitedImugene Limited-0.1--1937%-0.7
$-0.01

Current Fair Value

124.5% downside

Overvalued by 124.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$10.82 Million
Enterprise Value$14.48 Million
Earnings per Share$-0.32
Beta2.15
Outstanding Shares349,062,989

Return

Return on Equity-1936.76%ROE
Return on Assets-757.64%
Return on Invested Capital-1595.50%

Valuation & Multiples

P/E Ratio-0.11P/E Ratio
PEG-0.05PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue3.29
Enterprise Value to EBIT-0.1
Enterprise Value to Net Income-1
Total Debt to Enterprise0.43
Debt to Equity0.7Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 28, 2026
EPS
-$0.10
Est. -$0.03
Revenue
$449,664
Est. $968,506

Next Earnings Call

Expected Date
March 3, 2027
EPS Estimate
-$0.02
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Imugene Limited

14 employees
CEO: Leslie Chong

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an...